Navigation Links
KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid
Date:8/7/2009

future events and trends.

All statements that address expectations or projections about the future, including without limitation, product development, product launches, regulatory approvals, market position, acquisitions, sale of assets, revenues, expenditures, resumption of manufacturing and distribution of products and the impact of the recall and suspension of shipments on revenues, and other financial results, are forward-looking statements.

All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions, the Company provides the following cautionary statements identifying important economic, political and technological factors, which among others, could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.

Such factors include (but are not limited to) the following: (1) the ability to continue as a going concern; (2) changes in the current and future business environment, including interest rates and capital and consumer spending; (3) the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized; (4) the possibility of not obtaining FDA approvals or delay in obtaining FDA approvals; (5) acceptance and demand for new pharmaceutical products; (6) the introduction and impact of competitive products and pricing, including as a result of so-called authorized-generic drugs; (7) new product development and launch, including the possibility that any product launch may be delayed or that product acceptance may be less than anticipated; (8) reliance on key strategic alliances; (9) the availability of raw materials and/or products manufactured for the Company under contract manufacturing arrangements with third parties; (10) the regulatory environment, including regulatory agency an
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results
2. Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes
3. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
4. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
5. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
6. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
7. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
8. ADVENTRX Pharmaceuticals Announces Financing
9. Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock
10. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
11. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 China Biologic Products, Inc. (NASDAQ: ... fully integrated plasma-based biopharmaceutical company in ... subsidiary, Shandong Taibang Biological Products Co. Ltd., has ... China Food and Drug Administration (the "CFDA") for ... disclosed in the Company,s public filings, the CFDA ...
(Date:12/24/2014)... PharmaBoardroom,s new report, , Healthcare and Life ... free download , digs deep into this vibrant market, speaking ... today. One area where Algeria ... homegrown pharmaceutical manufacturing base, even if the government,s ambitious target ... A cursory comparison with neighboring Morocco ...
(Date:12/24/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ) ... Application (CTA) with the United Kingdom,s ... approval to initiate clinical trials for the continued development ... on the Company receiving CTA regulatory approval, the Company ... the safety, tolerability and dose escalation of Anatabine Citrate ...
(Date:12/22/2014)... PA & Brussels (PRWEB) December 22, 2014 ... (CfPIE), the global leader of technical training across ... Society for Clinical Data Management (SCDM) to provide ... and certification programs —providing access to the more ... partnership extends SCDM members with 10% off when registering ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... FREMONT, Calif., April 1, 2008 WaferGen,Biosystems, ... developer of,state-of-the-art gene expression, genotyping, cell biology ... signing of an exclusive distribution,agreement for the ... in Germany. The distributor agreement covers WaferGen,s,entire ...
... 1, 2008 Vista Partners announced,today that it ... Corporation,(Nasdaq: ABMC ) and maintains its twelve ... Research at Vista Partners stated, "Sales,internationally continue to ... ABMC,s products exposure in numerous testing centers, continue,to ...
... Coverage With Regional Perspective, PHILADELPHIA and LONDON, ... of information solutions to the worldwide,research and business ... have been added to Web of Science. The ... regional rather than,international audience by approaching subjects from ...
Cached Biology Technology:WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany 2WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany 3WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany 4WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany 5Vista Partners Updates Coverage; Maintains $3.20 Target Price 2Thomson Scientific Begins Expansion of Web of Science 2
(Date:12/5/2014)...  Tute Genomics, a leader in cloud-based solutions for ... funding led by UK-based Eurovestech. Peak Ventures and a ... round. "We are at a pivotal time ... and seeks new approaches for the diagnosis, treatment and ... MBA, and CEO of Tute Genomics. "One of the ...
(Date:12/3/2014)... Calif. , Dec. 2, 2014   ... globally deployed, innovative test solutions for military, aerospace, ... newest version of its successful TS-900 PXI ... performance and features of high-end systems to customers ... outstanding value compared to traditional ATE. ...
(Date:11/21/2014)... According to a new market ... RFID, Access Control, Intrusion Detection, Parking Management, Under Vehicle ... Service Geography - Global Forecasts to 2020", published by ... be around $25 Billion in 2014 and is expected ... CAGR of 8.69%. Browse 116 market data ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... A new study spearheaded by the University ... environmental monitoring of institutional water systems can help ... better known as Legionnaires disease. Reported recently in ... 20-hospital study also calls for reconsideration of the ...
... had to rely on time-consuming and uncertain behavioural examinations ... multiple sclerosis, Alzheimer,s and schizophrenia. ,Research published next ... Engineering suggests that we could soon be able to ... the tiny magnetic fields produced by neuron activity in ...
... the heat, its a sign that somethings wrongand a ... But turning up the temperature can have a down ... children, high fever can trigger fever-induced (febrile) seizures. While ... resulting from infection or heatstroke of over 108˚F (42˚C) ...
Cached Biology News:Study finds environmental tests help predict hospital-acquired Legionnaires' disease risk 260 second test could help early diagnosis of common brain diseases 2Feeling hot, hot, hot: New study suggests ways to control fever-induced seizures 2
... The Jouan RC Maxi MB (for ... of vacuum concentrator/centrifugal evaporator systems respond to ... for rapid and safe concentration of heat-labile ... with pumps, different of cold traps and ...
... The DNA120 is a dedicated concentrator for ... precipitates of DNA/RNA. The integrated system combines ... pump. The compact design, automatic pump and ... run time; one for heater time), makes ...
... kit. Includes configured Laptop PC with PCR ... MultiBlock satellite thermal Cycler (non-robotic). System ... software. Store/track run data. Gradient ... Outstanding uniformity. Advanced control algorithms for ...
... The Px2 Thermal Cycler is Thermo ... machine to date with easy to use ... display for easy programming. Designed to offer ... the Px2 incorporates a number of customer ...
Biology Products: